Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
HIV Med ; 14(2): 65-76, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22808988

ABSTRACT

OBJECTIVES: As socioeconomic factors may impact the risk of chronic kidney disease (CKD), we evaluated the incidence and risk factors of incident CKD among an HIV-infected cohort with universal access to health care and minimal injecting drug use (IDU). METHODS: Incident CKD was defined as an estimated glomerular filteration rate (eGFR) <60 ml/min/1.73 m(2) for ≥ 90 days. eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Rates were calculated per 1000 person-years (PY). Associations with outcomes were assessed using two separate Cox proportional hazard models, adjusting for baseline and time-updated covariates. RESULTS: Among 3360 participants [median age 29 years; 92% male; 44% African American (AA)] contributing 23,091 PY of follow-up, 116 developed incident CKD [5.0/1000 PY; 95% confidence interval (CI) 4.2-6.0/1000 PY]. The median first eGFR value was 97.0 mL/min/1.73 m(2) [interquartile range (IQR) 85.3-110.1 mL/min/1.73 m(2)]. Baseline factors associated with CKD included older age, lower CD4 count at HIV diagnosis [compared with CD4 count ≥ 500 cells/µL, hazard ratio (HR) 2.1 (95% CI 1.2-3.8) for CD4 count 350-499 cells/µL; HR 3.6 (95% CI 2.0-6.3) for CD4 count 201-349 cells/µL; HR 4.3 (95% CI 2.0-9.4) for CD4 count ≤ 200 cells/µL], and HIV diagnosis in the pre-highly active antiretroviral therapy (HAART) era. In the time-updated model, low nadir CD4 counts, diabetes, hepatitis B, hypertension and less HAART use were also associated with CKD. AA ethnicity was not associated with incident CKD in either model. CONCLUSIONS: The low incidence of CKD and the lack of association with ethnicity observed in this study may in part be attributable to unique features of our cohort such as younger age, early HIV diagnosis, minimal IDU, and unrestricted access to care. Lower baseline CD4 counts were significantly associated with incident CKD, suggesting early HIV diagnosis and timely introduction of HAART may reduce the burden of CKD.


Subject(s)
AIDS-Associated Nephropathy/epidemiology , HIV Seropositivity/epidemiology , Health Services Accessibility , Military Personnel/statistics & numerical data , Renal Insufficiency, Chronic/epidemiology , AIDS-Associated Nephropathy/etiology , AIDS-Associated Nephropathy/physiopathology , Adult , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , Disease Progression , Female , Glomerular Filtration Rate , HIV Seropositivity/complications , HIV Seropositivity/physiopathology , HIV-1 , Health Services Accessibility/statistics & numerical data , Humans , Incidence , Incidental Findings , Male , Proportional Hazards Models , Renal Insufficiency, Chronic/diagnosis , Renal Insufficiency, Chronic/etiology , Renal Insufficiency, Chronic/physiopathology , Risk Factors , United States/epidemiology , Viral Load
2.
Ann N Y Acad Sci ; 1170: 543-52, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19686191

ABSTRACT

Taste or gustatory function may play an important role in determining diet and nutritional status and therefore indirectly impact health. Yet there have been few attempts to study the spectrum of taste function and dysfunction in human populations. Epidemiologic studies are needed to understand the impact of taste function and dysfunction on public health, to identify modifiable risk factors, and to develop and test strategies to prevent clinically significant dysfunction. However, measuring taste function in epidemiologic studies is challenging and requires repeatable, efficient methods that can measure change over time. Insights gained from translating laboratory-based methods to a population-based study, the Beaver Dam Offspring Study (BOSS) will be shared. In this study, a generalized labeled magnitude scale (gLMS) method was used to measure taste intensity of filter paper disks saturated with salt, sucrose, citric acid, quinine, or 6-n-propylthiouracil, and a gLMS measure of taste preferences was administered. In addition, a portable, inexpensive camera system to capture digital images of fungiform papillae and a masked grading system to measure the density of fungiform papillae were developed. Adult children of participants in the population-based Epidemiology of Hearing Loss Study in Beaver Dam, Wisconsin, are eligible for this ongoing study. The parents were residents of Beaver Dam and 43-84 years of age in 1987-1988; offspring ranged in age from 21-84 years in 2005-2008. Methods will be described in detail and preliminary results about the distributions of taste function in the BOSS cohort will be presented.


Subject(s)
Taste Disorders/epidemiology , Adult , Aged , Aged, 80 and over , Humans , Middle Aged , Population Surveillance , Tongue/anatomy & histology , Wisconsin/epidemiology
3.
Am J Epidemiol ; 164(8): 733-41, 2006 Oct 15.
Article in English | MEDLINE | ID: mdl-16896053

ABSTRACT

The relation between herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus (HIV) acquisition was evaluated among 4,295 high-risk, HIV-negative men who have sex with men in an intensive behavioral intervention (colloquially referred to as "EXPLORE") study in the United States from 1999 to 2003. Sexual behavior data were obtained by computer-assisted self-interview, and sera were collected semiannually for HIV and HSV-2 serology. HSV-2 infection was classified as "recent incident" (at the first HSV-2 seropositive visit), "remote incident" (within 24 months of the first positive visit), and "prevalent" (for visits >24 months after the first HSV-2 positive visit). Baseline HSV-2 prevalence was 20.3%. HSV-2 incidence was 1.9 (95% confidence interval (CI): 1.6, 2.2) per 100 person-years; significant risk factors were African-American race, unprotected receptive anal intercourse, an HIV-positive male sex partner, and six or more male partners in the prior 6 months. The behavioral intervention did not reduce HSV-2 acquisition (adjusted hazard ratio (HR) = 1.2, 95% CI: 0.9, 1.6). Overall HIV incidence was 1.9 (95% CI: 1.7, 2.2) per 100 person-years. HIV risk was elevated among men who have sex with men with recent incident HSV-2 (adjusted HR = 3.6, 95% CI: 1.7, 7.8), remote incident HSV-2 (adjusted HR = 1.7, 95% CI: 0.8, 3.3), and prevalent HSV-2 (adjusted HR = 1.5, 95% CI: 1.1, 2.1) infection compared with HSV-2 seronegative participants. HIV intervention strategies targeting HSV-2 prevention and suppression among men who have sex with men should be evaluated.


Subject(s)
HIV Infections/epidemiology , Herpes Genitalis/epidemiology , Adolescent , Adult , Bisexuality , Blotting, Western , HIV Infections/transmission , Herpes Genitalis/transmission , Herpes Genitalis/virology , Herpesvirus 2, Human/isolation & purification , Homosexuality, Male , Humans , Incidence , Interviews as Topic , Male , Prevalence , Proportional Hazards Models , Prospective Studies , Randomized Controlled Trials as Topic , Risk Factors , Sexual Behavior , United States/epidemiology
4.
Clin Infect Dis ; 39(6): 842-9, 2004 Sep 15.
Article in English | MEDLINE | ID: mdl-15472817

ABSTRACT

BACKGROUND: Severely immunocompromised individuals are highly susceptible to Candida infection of the esophagus. This randomized, double-blind study assessed the dose-response relationship of the new echinocandin antifungal, micafungin, compared with that of standard fluconazole treatment. METHODS: A total of 245 patients (age, > or =18 years) with a prior diagnosis of acquired immunodeficiency syndrome/human immunodeficiency virus (HIV) infection and esophageal candidiasis, confirmed by endoscopy and culture, were randomized to receive micafungin (50, 100, or 150 mg per day) or fluconazole (200 mg per day). Both agents were administered once per day by a 1-h intravenous infusion for 14-21 days. The primary efficacy end point was endoscopic cure rate, defined as endoscopy grade of 0 at the end of therapy. RESULTS: The endoscopic cure rate (grade 0) was dose-dependent with 50, 100, and 150 mg of micafungin per day at 68.8%, 77.4%, and 89.8%, respectively. Symptoms improved or resolved rapidly (3-7 days of treatment in the majority of patients). The endoscopic cure rate for 100 and 150 mg of micafungin per day (83.5%) was comparable to that for 200 mg of fluconazole per day (86.7%; 95% confidence interval for the difference in endoscopic cure rate, -14.0% to 7.7%). The overall safety and tolerability was acceptable, with no important differences between micafungin (all doses) and fluconazole. CONCLUSIONS: The dose-response findings demonstrate a greater efficacy with micafungin at 100 and 150 mg per day than at 50 mg per day. This study also indicates that the efficacy of micafungin (at dosages of 100 and 150 mg per day) was comparable to that of fluconazole, suggesting that micafungin represents a valuable new treatment option for esophageal candidiasis in HIV-positive patients.


Subject(s)
AIDS-Related Opportunistic Infections/drug therapy , Antifungal Agents/therapeutic use , Candidiasis/drug therapy , Esophageal Diseases/microbiology , Fluconazole/therapeutic use , Lipoproteins/therapeutic use , Peptides, Cyclic/therapeutic use , Adolescent , Adult , Aged , Antifungal Agents/administration & dosage , Double-Blind Method , Echinocandins , Esophageal Diseases/drug therapy , Female , Fluconazole/administration & dosage , HIV Infections/complications , Humans , Lipopeptides , Lipoproteins/administration & dosage , Male , Micafungin , Middle Aged , Peptides, Cyclic/administration & dosage
5.
Sex Transm Infect ; 80(4): 272-6, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15295123

ABSTRACT

OBJECTIVES: Herpes simplex virus (HSV) 1 and HSV-2 reactivate preferentially in the oral and genital area, respectively. We aimed to define frequency and characteristics associated with oral shedding of HSV-2. METHODS: Demographic, clinical and laboratory data of patients with documented HSV-2 infection and at least one oral viral culture obtained were selected from the University of Washington Virology Research Clinic database. RESULTS: Of 1388 people meeting the entry criteria, 44 (3.2%) had HSV-2 isolated at least once from their mouths. In comparison with the 1344 people who did not have HSV-2 isolated from their mouth, participants with oral HSV-2 were more likely to be male (OR = 1.9, 95% CI 1.0 to 3.7), HIV positive (OR = 2.9, 95% CI 1.4 to 6.0), and homosexual (OR = 2.2, 95% CI 1.1 to 4.2), and to have collected a larger number of oral specimens (median 32 v 4, p<0.001). Of the 58 days with oral HSV-2 isolation, 15 (25%) occurred during newly acquired HSV-2 infection, 12 (21%) during a recurrence with genital lesions, three (5%) during a recurrence with oral lesions, and three (5%) during a recurrence with oral and genital lesions; 25 (43%) occurred during asymptomatic shedding. Oral HSV-2 was found less frequently than oral HSV-1 (0.06% v 1%, p<0.001) in people with HSV-1 and HSV-2 antibody, and less frequently than genital HSV-2 (0.09% v 7%, p<0.001). CONCLUSIONS: Oral reactivation of HSV-2 as defined by viral isolation is uncommon and usually occurs in the setting of first episode of genital HSV-2 or during genital recurrence of HSV-2.


Subject(s)
Herpes Genitalis/virology , Herpes Simplex/virology , Herpesvirus 2, Human/isolation & purification , Mouth Diseases/virology , Virus Shedding , Adolescent , Adult , Cohort Studies , Female , Humans , Male , Middle Aged , Risk Factors
7.
Br J Anaesth ; 52(9): 945-9, 1980 Sep.
Article in English | MEDLINE | ID: mdl-7437231

ABSTRACT

A 55-yr-old male undergoing varicose vein surgery with an extradural block complained of chest pain. E.c.g. changes and subsequent examination of the heart including coronary angiography suggested the diagnosis of Prinzmetal's variant angina. The therapeutic implications of this condition in patients undergoing anaesthesia and surgery are discussed.


Subject(s)
Anesthesia, Epidural , Angina Pectoris, Variant/diagnosis , Angina Pectoris/diagnosis , Intraoperative Complications/diagnosis , Coronary Angiography , Electrocardiography , Humans , Male , Middle Aged , Varicose Veins/surgery
8.
S Afr Med J ; 58(4): 161-2, 1980 Jul 26.
Article in English | MEDLINE | ID: mdl-7404209

ABSTRACT

The efficacy of low-dose intramuscular ketamine and hyaluronidase as an induction agent was studied in non-premedicated paediatric outpatients. With 40-50% of the hitherto minimum recommended dose a high success rate of induction was achieved, while the recovery time was considered satisfactory for outpatient anaesthesia. Side-effects were minimal and there were no instances of unpleasant dreams or emergence phenomena.


Subject(s)
Anesthesia, General/methods , Hyaluronoglucosaminidase , Ketamine , Body Weight , Child , Drug Therapy, Combination , Humans , Injections, Intramuscular , Outpatient Clinics, Hospital , Preanesthetic Medication
10.
Br J Anaesth ; 51(5): 457-9, 1979 May.
Article in English | MEDLINE | ID: mdl-444347

ABSTRACT

Haemoptysis occurred in a patient in whom a Swan-Ganz catheter was inserted for the induction of anaesthesia for hemicolectomy. It is suggested that acute pulmonary hypertension, superimposed on existing chronic pulmonary hypertension, superimposed on existing chronic pulmonary hypertension associated with mitral stenosis, was an important aetiological factor in the haemoptysis.


Subject(s)
Cardiac Catheterization/adverse effects , Hemoptysis/etiology , Acute Disease , Aged , Humans , Hypertension, Pulmonary/complications , Male
12.
Br J Surg ; 63(2): 110-2, 1976 Feb.
Article in English | MEDLINE | ID: mdl-943201

ABSTRACT

A case is presented of ascites and hydrothorax in association with struma ovarii. Nine previously reported cases are reviewed and the possible causes of the ascites and hydrothorax discussed.


Subject(s)
Ascites/complications , Hydrothorax/complications , Struma Ovarii/complications , Ascites/etiology , Female , Humans , Hydrothorax/etiology , Meigs Syndrome , Middle Aged , Ovary/pathology , Struma Ovarii/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...